Piedmont Investment Advisors’s Adicet Bio ACET Stock Holding History

Piedmont Investment Advisors’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1	Closed	-$1K	–	1047
2018 Q2	$1K	Buy	+1	New	+$1.08K	﹤0.01%	2718

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Piedmont Investment Advisors's ACET Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Adicet Bio (ACET) in Q3 2018, closing a stake of 1 share — an estimated $1K sold.

Piedmont Investment Advisors first reported a position in ACET in Q2 2018 and held it in 1 quarter. The position peaked at $1K in Q2 2018. 40 funds tracked by Wall St. Rank hold ACET as of Q3 2018.

Piedmont Investment Advisors reported no remaining Adicet Bio position as of Q3 2018 after selling out during the quarter.
Piedmont Investment Advisors sold 1 Adicet Bio share in Q3 2018, an estimated $1K.
Piedmont Investment Advisors first reported a position in Adicet Bio in Q2 2018 and held it in 1 quarter.
Piedmont Investment Advisors's Adicet Bio position peaked at $1K in Q2 2018.
40 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.